Effectiveness of Varenicline as an Aid to Smoking Cessation in Primary Care: An Observational Study
2013 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Effectiveness of Varenicline as an Aid to Smoking Cessation in Primary Care: An Observational Study
Andreas, S.; Chenot, J.-F.; Diebold, R.; Peachey, S. & Mann, K. (2013)
European Addiction Research, 19(1) pp. 47-54. DOI: https://doi.org/10.1159/000341638
Documents & Media
Details
- Authors
- Andreas, Stefan; Chenot, Jean-Francois; Diebold, Ruth; Peachey, Sarah; Mann, Karl
- Abstract
- Aims: Although varenicline is commonly prescribed in primary care, information on smoking-related comorbidities and the effectiveness of varenicline in this context in Germany is scarce. This study assessed the efficacy and safety of varenicline in a large sample of patients seeking smoking cessation treatment through their general practitioners. The frequency of comorbidities was also evaluated. Methods: This was a 12-week, prospective, observational, non-comparative phase IV trial conducted in Germany. Abstinence rates at week 12 were evaluated by verbal reporting using the nicotine use inventory. Results: Overall, 1,391 subjects were enrolled; 1,177 received study medication and were evaluated for effectiveness and safety. At the end of the study, 71.1% (95% confidence interval 68.5-73.7) of subjects were abstinent. There were a total of 205 all-causality adverse events; 2.2% were classified as serious or severe. There were no fatal adverse events. At inclusion, 66.7% of participants had at least 1 concurrent comorbidity, with chronic obstructive pulmonary disease (35.5%), hypertension (29.6%) and depression (10.4%) being the most commonly reported. Conclusion: These real-world data indicate that varenicline is an effective and well-tolerated smoking cessation treatment when used in the primary care setting including patients with smoking-related comorbidities. Copyright (C) 2012 S. Karger AG, Basel
- Issue Date
- 2013
- Status
- published
- Publisher
- Karger
- Journal
- European Addiction Research
- ISSN
- 1022-6877
- Sponsor
- Pfizer Inc.; Alkermes; Lundbeck; McNeil; MundiPharma; Merck Sharp Dohme